STING1 and neoplasm: Engineered strains that express l-arginine, PD-L1, CTLA-4 nanobodies, or STING agonists have demonstrated significant efficacy in inducing immune-mediated tumor control in preclinical studies and are progressing toward clinical trials (Luke et al., 2023).